Document:

<PAGE>

                                                                   Exhibit 10.2

                                 CRDENTIA CORP.

                          NOTICE OF STOCK OPTION AWARD
                          ----------------------------

         Grantee's Name and Address:      William S. Leftwich
                                          521 Spinner Road
                                          De Soto, Texas 75115

         You (the "Grantee") have been granted an option to purchase shares of
Common Stock, subject to the terms and conditions of this Notice of Stock Option
Award (the "Notice") and the Stock Option Award Agreement (the "Option
Agreement") attached hereto, as follows. Unless otherwise defined herein, the
terms defined in the Option Agreement shall have the same defined meanings in
this Notice.

         Award Number                                5

         Date of Award                               April 8, 2004

         Vesting Commencement Date                   November 7, 2003

         Exercise Price per Share                    $1.05

         Total Number of Shares Subject
         to the Option (the "Shares")                331,512

         Total Exercise Price                        $348,087.60

         Type of Option                              Non-Qualified Stock Option

         Expiration Date:                            April 8, 2014

         Post-Termination Exercise Period:           Three (3) Months

Vesting Schedule:
-----------------

         Subject to the Grantee's Continuous Service and other limitations set
forth in this Notice and the Option Agreement, the Option may be exercised, in
whole or in part, in accordance with the following schedule:

         1/4th of the Total Number of Shares Subject to the Option shall vest
upon the first anniversary of the Vesting Commencement Date, and 1/48th of the
Total Number of Shares Subject to the Option shall thereafter vest in a series
of thirty six (36) successive equal monthly installments upon Grantee's
completion of each additional month of service to the Company such that the
Option will be fully vested four (4) years after the Vesting Commencement Date.

         During any authorized leave of absence, the vesting of the Option as
provided in this schedule shall be suspended after the leave of absence exceeds
a period of ninety (90) days. Vesting of the Option shall resume upon the
Grantee's termination of the leave of absence and return to service to the
Company or a Related Entity. The Vesting Schedule of the Option shall be
extended by the length of the suspension.

                                       1
<PAGE>

         In the event of termination of the Grantee's Continuous Service for
Cause, the Grantee's right to exercise the Option shall terminate concurrently
with the termination of the Grantee's Continuous Service, except as otherwise
determined by the Board.

         In the event of the Grantee's change in status from Employee to
Consultant or from an Employee whose customary employment is 20 hours or more
per week to an Employee whose customary employment is fewer than 20 hours per
week, vesting of the Option shall continue only to the extent determined by the
Board as of such change in status.

         IN WITNESS WHEREOF, the Company and the Grantee have executed this
Notice and agree that the Option is to be governed by the terms and conditions
of this Notice and the Option Agreement.

                                                 Crdentia Corp.,
                                                 a Delaware corporation

                                                 By:  /s/ Pamela Atherton
                                                      -------------------------
                                                      Pamela Atherton
                                                      President

THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE SHARES SUBJECT TO THE OPTION SHALL
VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE'S CONTINUOUS SERVICE (NOT
THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE OPTION OR ACQUIRING SHARES
HEREUNDER). THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS
NOTICE OR THE OPTION AGREEMENT SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH
RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE'S CONTINUOUS SERVICE,
NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE'S RIGHT OR THE RIGHT OF THE
COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE
THE GRANTEE'S CONTINUOUS SERVICE, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT
NOTICE. THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN
EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE'S STATUS IS
AT WILL.

         The Grantee acknowledges receipt of a copy of the Option Agreement, and
represents that he or she is familiar with the terms and provisions thereof, and
hereby accepts the Option subject to all of the terms and provisions hereof and
thereof. The Grantee has reviewed this Notice and the Option Agreement in their
entirety, has had an opportunity to obtain the advice of counsel prior to
executing this Notice, and fully understands all provisions of this Notice and
the Option Agreement. The Grantee hereby agrees that all disputes arising out of
or relating to this Notice and the Option Agreement shall be resolved in
accordance with Section 17 of the Option Agreement. The Grantee further agrees
to notify the Company upon any change in the residence address indicated in this
Notice.

Dated:  April 8, 2004                      Signed:  /s/ William S. Leftwich
                                                    ----------------------------
                                                    William S. Leftwich, Grantee

                                       2
<PAGE>

                                                                 AWARD NUMBER: 5

                                 CRDENTIA CORP.

                          STOCK OPTION AWARD AGREEMENT
                          ----------------------------

         1. GRANT OF OPTION. Crdentia Corp., a Delaware corporation (the
"Company"), hereby grants to the Grantee (the "Grantee") named in the Notice of
Stock Option Award (the "Notice"), an option (the "Option") to purchase the
Total Number of Shares of Common Stock subject to the Option (the "Shares") set
forth in the Notice, at the Exercise Price per Share set forth in the Notice
(the "Exercise Price") subject to the terms and provisions of this Stock Option
Award Agreement (the "Option Agreement") and the Notice which are incorporated
herein by reference.

         2. EXERCISE OF OPTION.

                  (a) RIGHT TO EXERCISE. The Option shall be exercisable during
its term in accordance with the Vesting Schedule set out in the Notice and with
the applicable provisions of this Option Agreement. The Option shall be subject
to the provisions of Section 20 of this Option Agreement relating to the
exercisability or termination of the Option in the event of a Corporate
Transaction. The Grantee shall be subject to reasonable limitations on the
number of requested exercises during any monthly or weekly period as determined
by the Board. In no event shall the Company issue fractional Shares.

                  (b) METHOD OF EXERCISE. The Option shall be exercisable by
delivery of an exercise notice (a form of which is attached as Exhibit A) or by
such other procedure as specified from time to time by the Board which shall
state the election to exercise the Option, the whole number of Shares in respect
of which the Option is being exercised, and such other provisions as may be
required by the Board. The exercise notice shall be delivered in person, by
certified mail, or by such other method (including electronic transmission) as
determined from time to time by the Board to the Company accompanied by payment
of the Exercise Price. The Option shall be deemed to be exercised upon receipt
by the Company of such notice accompanied by the Exercise Price, which, to the
extent selected, shall be deemed to be satisfied by use of the broker-dealer
sale and remittance procedure to pay the Exercise Price provided in Section
4(d), below.

                  (c) TAXES. No Shares will be delivered to the Grantee or other
person pursuant to the exercise of the Option until the Grantee or other person
has made arrangements acceptable to the Board for the satisfaction of applicable
income tax and employment tax withholding obligations, including, without
limitation, obligations incident to the receipt of Shares. Upon exercise of the
Option, the Company or the Grantee's employer may offset or withhold (from any
amount owed by the Company or the Grantee's employer to the Grantee) or collect
from the Grantee or other person an amount sufficient to satisfy such tax
obligations and/or the employer's withholding obligations.

         3. GRANTEE'S REPRESENTATIONS. The Grantee understands that neither the
Option nor the Shares exercisable pursuant to the Option have been registered
under the Securities Act of 1933, as amended, or any United States securities

                                       3
<PAGE>

laws. In the event the Shares purchasable pursuant to the exercise of the Option
have not been registered under the Securities Act of 1933, as amended, at the
time the Option is exercised, the Grantee shall, if requested by the Company,
concurrently with the exercise of all or any portion of the Option, deliver to
the Company his or her Investment Representation Statement in the form attached
hereto as Exhibit B.

         4. METHOD OF PAYMENT. Payment of the Exercise Price shall be made by
any of the following, or a combination thereof, at the election of the Grantee;
provided, however, that such exercise method does not then violate any
Applicable Law and, provided further, that the portion of the Exercise Price
equal to the par value of the Shares must be paid in cash or other legal
consideration permitted by the Delaware General Corporation Law:

                  (a) cash;

                  (b) check;

                  (c) surrender of Shares or delivery of a properly executed
form of attestation of ownership of Shares as the Board may require which have a
Fair Market Value on the date of surrender or attestation equal to the aggregate
Exercise Price of the Shares as to which the Option is being exercised,
provided, however, that Shares acquired under the Option or any other equity
compensation plan or agreement of the Company must have been held by the Grantee
for a period of more than six (6) months; or

                  (d) payment through a broker-dealer sale and remittance
procedure pursuant to which the Grantee (i) shall provide written instructions
to a Company-designated brokerage firm to effect the immediate sale of some or
all of the purchased Shares and remit to the Company sufficient funds to cover
the aggregate exercise price payable for the purchased Shares and (ii) shall
provide written directives to the Company to deliver the certificates for the
purchased Shares directly to such brokerage firm in order to complete the sale
transaction.

         5. RESTRICTIONS ON EXERCISE. The Option may not be exercised if the
issuance of the Shares subject to the Option upon such exercise would constitute
a violation of any Applicable Laws.

         6. TERMINATION OR CHANGE OF CONTINUOUS SERVICE. In the event the
Grantee's Continuous Service terminates, other than for Cause, the Grantee may,
but only during the Post-Termination Exercise Period, exercise the portion of
the Option that was vested at the date of such termination (the "Termination
Date"). In the event of termination of the Grantee's Continuous Service for
Cause, the Grantee's right to exercise the Option shall, except as otherwise
determined by the Board, terminate concurrently with the termination of the
Grantee's Continuous Service (also the "Termination Date"). In no event shall
the Option be exercised later than the Expiration Date set forth in the Notice.
In the event of the Grantee's change in status from Employee, Director or
Consultant to any other status of Employee, Director or Consultant, the Option
shall remain in effect and vesting of the Option shall continue only to the
extent determined by the Board as of such change in status. Except as provided
in Sections 7 and 8 below, to the extent that the Option was unvested on the

                                       4
<PAGE>

Termination Date, or if the Grantee does not exercise the vested portion of the
Option within the Post-Termination Exercise Period, the Option shall terminate.

         7. DISABILITY OF GRANTEE. In the event the Grantee's Continuous Service
terminates as a result of his or her Disability, the Grantee may, but only
within twelve (12) months from the Termination Date (and in no event later than
the Expiration Date), exercise the portion of the Option that was vested on the
Termination Date. To the extent that the Option was unvested on the Termination
Date, or if the Grantee does not exercise the vested portion of the Option
within the time specified herein, the Option shall terminate.

         8. DEATH OF GRANTEE. In the event of the termination of the Grantee's
Continuous Service as a result of his or her death, or in the event of the
Grantee's death during the Post-Termination Exercise Period or during the twelve
(12) month period following the Grantee's termination of Continuous Service as a
result of his or her Disability, the Grantee's estate, or a person who acquired
the right to exercise the Option by bequest or inheritance, may exercise the
portion of the Option that was vested at the date of termination within twelve
(12) months from the date of death (but in no event later than the Expiration
Date). To the extent that the Option was unvested on the date of death, or if
the vested portion of the Option is not exercised within the time specified
herein, the Option shall terminate.

         9. TRANSFERABILITY OF OPTION. The Option may not be transferred in any
manner other than by will or by the laws of descent and distribution, provided,
however, that the Option may be transferred to members of the Grantee's
Immediate Family to the extent and in the manner authorized by the Board.
Notwithstanding the foregoing, the Grantee may designate members of the
Grantee's Immediate Family as beneficiaries of the Grantee's Option in the event
of the Grantee's death on a beneficiary designation form provided by the Board.
The terms of the Option shall be binding upon the executors, administrators,
heirs and successors of the Grantee.

         10. TERM OF OPTION. The Option must be exercised no later than the
Expiration Date set forth in the Notice or such earlier date as otherwise
provided herein. After the Expiration Date or such earlier date, the Option
shall be of no further force or effect and may not be exercised.

         11. STOP-TRANSFER NOTICES. In order to ensure compliance with the
restrictions on transfer set forth in this Option Agreement or the Notice, the
Company may issue appropriate "stop transfer" instructions to its transfer
agent, if any, and, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records.

         12. REFUSAL TO TRANSFER. The Company shall not be required (i) to
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Option Agreement or (ii) to treat as
owner of such Shares or to accord the right to vote or pay dividends to any
purchaser or other transferee to whom such Shares shall have been so
transferred.

         13. TAX CONSEQUENCES. Set forth below is a brief summary as of the date
of this Option Agreement of some of the federal tax consequences of exercise of
the Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY

                                       5
<PAGE>

INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THE GRANTEE
SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE
SHARES.

                  (a) EXERCISE OF NON-QUALIFIED STOCK OPTION. On exercise of a
Non-Qualified Stock Option, the Grantee will be treated as having received
compensation income (taxable at ordinary income tax rates) equal to the excess,
if any, of the Fair Market Value of the Shares on the date of exercise over the
Exercise Price. If the Grantee is an Employee or a former Employee, the Company
will be required to withhold from the Grantee's compensation or collect from the
Grantee and pay to the applicable taxing authorities an amount in cash equal to
a percentage of this compensation income at the time of exercise, and may refuse
to honor the exercise and refuse to deliver Shares if such withholding amounts
are not delivered at the time of exercise.

                  (b) DISPOSITION OF SHARES. If Shares are held for more than
one year, any gain realized on disposition of the Shares will be treated as
long-term capital gain for federal income tax purposes.

         14. LOCK-UP AGREEMENT.

                  (a) AGREEMENT. The Grantee, if requested by the Company and
the lead underwriter of any public offering of the Common Stock (the "Lead
Underwriter"), hereby irrevocably agrees not to sell, contract to sell, grant
any option to purchase, transfer the economic risk of ownership in, make any
short sale of, pledge or otherwise transfer or dispose of any interest in any
Common Stock or any securities convertible into or exchangeable or exercisable
for or any other rights to purchase or acquire Common Stock (except Common Stock
included in such public offering or acquired on the public market after such
offering) during the 180-day period following the effective date of a
registration statement of the Company filed under the Securities Act of 1933, as
amended, or such shorter period of time as the Lead Underwriter shall specify.
The Grantee further agrees to sign such documents as may be requested by the
Lead Underwriter to effect the foregoing and agrees that the Company may impose
stop-transfer instructions with respect to such Common Stock subject to the
lock-up period until the end of such period. The Company and the Grantee
acknowledge that each Lead Underwriter of a public offering of the Company's
stock, during the period of such offering and for the 180-day period thereafter,
is an intended beneficiary of this Section 14.

                  (b) NO AMENDMENT WITHOUT CONSENT OF UNDERWRITER. During the
period from identification of a Lead Underwriter in connection with any public
offering of the Company's Common Stock until the earlier of (i) the expiration
of the lock-up period specified in Section 14(a) in connection with such
offering or (ii) the abandonment of such offering by the Company and the Lead
Underwriter, the provisions of this Section 14 may not be amended or waived
except with the consent of the Lead Underwriter.

         15. ENTIRE AGREEMENT: GOVERNING LAW. The Notice and this Option
Agreement constitute the entire agreement of the parties with respect to the
subject matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and the Grantee with respect to the subject matter

                                       6
<PAGE>

hereof, and may not be modified adversely to the Grantee's interest except by
means of a writing signed by the Company and the Grantee. Nothing in the Notice
and this Option Agreement (except as expressly provided therein) is intended to
confer any rights or remedies on any persons other than the parties. The Notice
and this Option Agreement are to be construed in accordance with and governed by
the internal laws of the State of Texas without giving effect to any choice of
law rule that would cause the application of the laws of any jurisdiction other
than the internal laws of the State of Texas to the rights and duties of the
parties. Should any provision of the Notice or this Option Agreement be
determined by a court of law to be illegal or unenforceable, such provision
shall be enforced to the fullest extent allowed by law and the other provisions
shall nevertheless remain effective and shall remain enforceable.

         16. HEADINGS. The captions used in the Notice and this Option Agreement
are inserted for convenience and shall not be deemed a part of the Option for
construction or interpretation.

         17. DISPUTE RESOLUTION. The provisions of this Section 17 shall be the
exclusive means of resolving disputes arising out of or relating to the Notice
and this Option Agreement. The Company, the Grantee, and the Grantee's assignees
(the "parties") shall attempt in good faith to resolve any disputes arising out
of or relating to the Notice and this Option Agreement by negotiation between
individuals who have authority to settle the controversy. Negotiations shall be
commenced by either party by notice of a written statement of the party's
position and the name and title of the individual who will represent the party.
Within thirty (30) days of the written notification, the parties shall meet at a
mutually acceptable time and place, and thereafter as often as they reasonably
deem necessary, to resolve the dispute. If the dispute has not been resolved by
negotiation, the parties agree that any suit, action, or proceeding arising out
of or relating to the Notice or this Option Agreement shall be brought in the
United States District Court for the Northern District of Texas (or should such
court lack jurisdiction to hear such action, suit or proceeding, in a Texas
state court in the County of Dallas) and that the parties shall submit to the
jurisdiction of such court. The parties irrevocably waive, to the fullest extent
permitted by law, any objection the party may have to the laying of venue for
any such suit, action or proceeding brought in such court. THE PARTIES ALSO
EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH
SUIT, ACTION OR PROCEEDING. If any one or more provisions of this Section 17
shall for any reason be held invalid or unenforceable, it is the specific intent
of the parties that such provisions shall be modified to the minimum extent
necessary to make it or its application valid and enforceable.

         18. NOTICES. Any notice required or permitted hereunder shall be given
in writing and shall be deemed effectively given upon personal delivery, upon
deposit for delivery by an internationally recognized express mail courier
service or upon deposit in the United States mail by certified mail (if the
parties are within the United States), with postage and fees prepaid, addressed
to the other party at its address as shown in these instruments, or to such
other address as such party may designate in writing from time to time to the
other party.

         19. ADJUSTMENTS UPON CHANGES IN CAPITALIZATION. Subject to any required
action by the stockholders of the Company, the number of Shares covered by the
Option, the exercise price of the Option, as well as any other terms that the

                                       7
<PAGE>

Board determines require adjustment shall be proportionately adjusted for (i)
any increase or decrease in the number of issued Shares resulting from a stock
split, reverse stock split, stock dividend, combination or reclassification of
the Shares, or similar transaction affecting the Shares, (ii) any other increase
or decrease in the number of issued Shares effected without receipt of
consideration by the Company, or (iii) as the Board may determine in its
discretion, any other transaction with respect to Common Stock including a
corporate merger, consolidation, acquisition of property or stock, separation
(including a spin-off or other distribution of stock or property),
reorganization, liquidation (whether partial or complete) or any similar
transaction; provided, however that conversion of any convertible securities of
the Company shall not be deemed to have been "effected without receipt of
consideration." Such adjustment shall be made by the Board and its determination
shall be final, binding and conclusive. Except as the Board determines, no
issuance by the Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and no adjustment
by reason hereof shall be made with respect to, the number or price of Shares
subject to the Option.

         20. CORPORATE TRANSACTIONS.

                  (a) TERMINATION OF OPTION TO EXTENT NOT ASSUMED IN CORPORATE
TRANSACTION. Effective upon the consummation of a Corporate Transaction, the
Option shall terminate. However, the Option shall not terminate to the extent it
is Assumed in connection with the Corporate Transaction.

                  (b) ACCELERATION OF OPTION UPON CORPORATE TRANSACTION. In the
event of a Corporate Transaction and:

                           (i) for the portion of the Option that is Assumed or
Replaced, then the Option (if Assumed), the replacement award (if Replaced), or
the cash incentive program (if Replaced) automatically shall become fully
vested, exercisable and payable for all of the Shares at the time represented by
such Assumed or Replaced portion of the Option, immediately upon termination of
the Grantee's Continuous Service if such Continuous Service is terminated by the
successor company, the Company or a Related Entity without Cause or voluntarily
by the Grantee with Good Reason within eighteen (18) months after the Corporate
Transaction; and

                           (ii) for the portion of the Option that is neither
Assumed nor Replaced, such portion of the Option shall automatically become
fully vested and exercisable for all of the Shares at the time represented by
such portion of the Option, immediately prior to the specified effective date of
such Corporate Transaction.

         21. DEFINITIONS. As used herein, the following definitions shall apply:

                  (a) "APPLICABLE LAWS" means the legal requirements applicable
to the Option under applicable provisions of federal securities laws, state
corporate and securities laws, the Code, the rules of any applicable stock
exchange or national market system, and the rules of any non-U.S. jurisdiction
applicable to Options granted to residents therein.

                                       8
<PAGE>

                  (b) "ASSUMED" means that pursuant to a Corporate Transaction
either (i) the Option is expressly affirmed by the Company or (ii) the
contractual obligations represented by the Option are expressly assumed (and not
simply by operation of law) by the successor entity or its Parent in connection
with the Corporate Transaction with appropriate adjustments to the number and
type of securities of the successor entity or its Parent subject to the Option
and the exercise or purchase price thereof which at least preserves the
compensation element of the Option existing at the time of the Corporate
Transaction as determined in accordance with the instruments evidencing the
agreement to assume the Option.

                  (c) "BOARD" means the Board of Directors of the Company and
shall include any committee of the Board or Officer of the Company to which the
Board has delegated its authority under this Agreement.

                  (d) "CAUSE" means, with respect to the termination by the
Company or a Related Entity of the Grantee's Continuous Service, that such
termination is for "Cause" as such term is expressly defined in a then-effective
written agreement between the Grantee and the Company or such Related Entity, or
in the absence of such then-effective written agreement and definition, is based
on, in the determination of the Board, the Grantee's: (i) performance of any act
or failure to perform any act in bad faith and to the detriment of the Company
or a Related Entity; (ii) dishonesty, intentional misconduct or material breach
of any agreement with the Company or a Related Entity; or (iii) commission of a
crime involving dishonesty, breach of trust, or physical or emotional harm to
any person.

                  (e) "CODE" means the Internal Revenue Code of 1986, as
amended.

                  (f) "COMMON STOCK" means the common stock of the Company.

                  (g) "COMPANY" means Crdentia Corp., a Delaware corporation.

                  (h) "CONSULTANT" means any person (other than an Employee or a
Director, solely with respect to rendering services in such person's capacity as
a Director) who is engaged by the Company or any Related Entity to render
consulting or advisory services to the Company or such Related Entity.

                  (i) "CONTINUOUS SERVICE" means that the provision of services
to the Company or a Related Entity in any capacity of Employee, Director or
Consultant is not interrupted or terminated. In jurisdictions requiring notice
in advance of an effective termination as an Employee, Director or Consultant,
Continuous Service shall be deemed terminated upon the actual cessation of
providing services to the Company or a Related Entity notwithstanding any
required notice period that must be fulfilled before a termination as an
Employee, Director or Consultant can be effective under Applicable Laws.
Continuous Service shall not be considered interrupted in the case of (i) any
approved leave of absence, (ii) transfers among the Company, any Related Entity,
or any successor, in any capacity of Employee, Director or Consultant, or (iii)
any change in status as long as the individual remains in the service of the
Company or a Related Entity in any capacity of Employee, Director or Consultant
(except as otherwise provided in the Option Agreement). An approved leave of
absence shall include sick leave, military leave, or any other authorized
personal leave.

                                       9
<PAGE>

                  (j) "CORPORATE TRANSACTION" means any of the following
transactions:

                           (i) a merger or consolidation in which the Company is
not the surviving entity, except for a transaction the principal purpose of
which is to change the state in which the Company is incorporated;

                           (ii) the sale, transfer or other disposition of all
or substantially all of the assets of the Company (including the capital stock
of the Company's subsidiary corporations);

                           (iii) the complete liquidation or dissolution of the
Company;

                           (iv) any reverse merger or series of related
transactions culminating in a reverse merger (including, but not limited to, a
tender offer followed by a reverse merger) in which the Company is the surviving
entity but in which securities possessing more than fifty percent (50%) of the
total combined voting power of the Company's outstanding securities are
transferred to a person or persons different from those who held such securities
immediately prior to such merger or the initial transaction culminating in such
merger but excluding any such transaction or series of related transactions that
the Board determines shall not be a Corporate Transaction; or

                           (v) acquisition in a single or series of related
transactions by any person or related group of persons (other than the Company
or by a Company-sponsored employee benefit plan) of beneficial ownership (within
the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more
than fifty percent (50%) of the total combined voting power of the Company's
outstanding securities but excluding any such transaction or series of related
transactions that the Board determines shall not be a Corporate Transaction.

                  (k) "DIRECTOR" means a member of the Board or the board of
directors of any Related Entity.

                  (l) "DISABILITY" shall have the same meaning as defined under
the long-term disability policy of the Company or the Related Entity to which
the Grantee provides services regardless of whether the Grantee is covered by
such policy. If the Company or the Related Entity to which the Grantee provides
service does not have a long-term disability plan in place, "Disability" means
that the Grantee is unable to carry out the responsibilities and functions of
the position held by the Grantee by reason of any medically determinable
physical or mental impairment for a period of not less than ninety (90)
consecutive days. The Grantee will not be considered to have incurred a
Disability unless he or she furnishes proof of such impairment sufficient to
satisfy the Board in its discretion.

                  (m) "EMPLOYEE" means any person, including an Officer or
Director, who is in the employ of the Company or any Related Entity, subject to
the control and direction of the Company or any Related Entity as to both the
work to be performed and the manner and method of performance. The payment of a
director's fee by the Company or a Related Entity shall not be sufficient to
constitute "employment" by the Company.

                                       10
<PAGE>

                  (n) "EXCHANGE ACT" means the Securities Exchange Act of 1934,
as amended.

                  (o) "FAIR MARKET VALUE" means, as of any date, the value of
Common Stock determined as follows:

                           (i) If the Common Stock is listed on any established
stock exchange or a national market system, including without limitation The
Nasdaq National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market,
its Fair Market Value shall be the closing sales price for such stock (or the
closing bid, if no sales were reported) as quoted on such exchange or system on
the date of determination (or, if no closing sales price or closing bid was
reported on that date, as applicable, on the last trading date such closing
sales price or closing bid was reported), as reported in The Wall Street Journal
or such other source as the Board deems reliable;

                           (ii) If the Common Stock is regularly quoted on an
automated quotation system (including the OTC Bulletin Board) or by a recognized
securities dealer, but selling prices are not reported, the Fair Market Value of
a Share of Common Stock shall be the mean between the high bid and low asked
prices for the Common Stock on date of determination (or, if no such prices were
reported on that date, on the last date such prices were reported), as reported
in The Wall Street Journal or such other source as the Board deems reliable; or

                           (iii) In the absence of an established market for the
Common Stock of the type described in (i) and (ii), above, the Fair Market Value
thereof shall be determined by the Board in good faith.

                  (p) "GOOD REASON" means the occurrence after a Corporate
Transaction of any of the following events or conditions unless consented to by
the Grantee (and the Grantee shall be deemed to have consented to any such event
or condition unless the Grantee provides written notice of the Grantee's
non-acquiescence within 30 days of the effective time of such event or
condition):

                           (i) a reduction in the Grantee's base salary to a
level more than fifteen percent (15%) below that in effect at any time within
six (6) months preceding the consummation of a Corporate Transaction or at any
time thereafter (not including a similar reduction with respect to all of the
Company's management); or

                           (ii) requiring the Grantee to be based at any place
outside a 50-mile radius from the Grantee's job location prior to the Corporate
Transaction except for reasonably required travel on business which is not
materially greater than such travel requirements prior to the Corporate
Transaction

                  (q) "IMMEDIATE FAMILY" means any child, stepchild, grandchild,
parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in law, daughter-in-law, brother-in-law, or
sister-in-law, including adoptive relationships, any person sharing the
Grantee's household (other than a tenant or employee), a trust in which these
persons (or the Grantee) have more than fifty percent (50%) of the beneficial
interest, a foundation in which these persons (or the Grantee) control the

                                       11
<PAGE>

management of assets, and any other entity in which these persons (or the
Grantee) own more than fifty percent (50%) of the voting interests.

                  (r) "NON-QUALIFIED STOCK OPTION" means an Option not intended
to qualify as an incentive stock option within the meaning of Section 422 of the
Code.

                  (s) "OFFICER" means a person who is an officer of the Company
or a Related Entity within the meaning of Section 16 of the Exchange Act and the
rules and regulations promulgated thereunder.

                  (t) "PARENT" means a "parent corporation," whether now or
hereafter existing, as defined in Section 424(e) of the Code.

                  (u) "RELATED ENTITY" means any Parent or Subsidiary of the
Company and any business, corporation, partnership, limited liability company or
other entity in which the Company or a Parent or a Subsidiary of the Company
holds a substantial ownership interest, directly or indirectly.

                  (v) "REPLACED" means that pursuant to a Corporate Transaction
the Option is replaced with a comparable stock award or a cash incentive program
of the Company, the successor entity (if applicable) or Parent of either of them
which preserves the compensation element of such Option existing at the time of
the Corporate Transaction and provides for subsequent payout in accordance with
the same (or a more favorable) vesting schedule applicable to such Option. The
determination of Option comparability shall be made by the Board and its
determination shall be final, binding and conclusive.

                  (w) "SHARE" means a share of the Common Stock.

                  (x) "SUBSIDIARY" means a "subsidiary corporation," whether now
or hereafter existing, as defined in Section 424(f) of the Code.

                                END OF AGREEMENT

                                       12
<PAGE>

                                    EXHIBIT A
                                    ---------

                                 EXERCISE NOTICE
                                 ---------------

Crdentia Corp.
14114 Dallas Parkway, Suite 600
Dallas, Texas  75254
Attention:  Secretary

         1. Effective as of today, ______________, ___ the undersigned (the
"Grantee") hereby elects to exercise the Grantee's option to purchase
___________ shares of the Common Stock (the "Shares") of Crdentia Corp. (the
"Company") under and pursuant to the Stock Option Award Agreement (the "Option
Agreement") and Notice of Stock Option Award (the "Notice") dated April 8, 2004.
Unless otherwise defined herein, the terms defined in the Option Agreement shall
have the same defined meanings in this Exercise Notice.

         2. REPRESENTATIONS OF THE GRANTEE. The Grantee acknowledges that the
Grantee has received, read and understood the Notice and the Option Agreement
and agrees to abide by and be bound by their terms and conditions.

         3. RIGHTS AS STOCKHOLDER. Until the stock certificate evidencing such
Shares is issued (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company), no right to vote
or receive dividends or any other rights as a stockholder shall exist with
respect to the Shares, notwithstanding the exercise of the Option. The Company
shall issue (or cause to be issued) such stock certificate promptly after the
Option is exercised. No adjustment will be made for a dividend or other right
for which the record date is prior to the date the stock certificate is issued,
except as provided in Section 19 of the Option Agreement.

         4. DELIVERY OF PAYMENT. The Grantee herewith delivers to the Company
the full Exercise Price for the Shares, which, to the extent selected, shall be
deemed to be satisfied by use of the broker-dealer sale and remittance procedure
to pay the Exercise Price provided in Section 19 of the Option Agreement.

         5. TAX CONSULTATION. The Grantee understands that the Grantee may
suffer adverse tax consequences as a result of the Grantee's purchase or
disposition of the Shares. The Grantee represents that the Grantee has consulted
with any tax consultants the Grantee deems advisable in connection with the
purchase or disposition of the Shares and that the Grantee is not relying on the
Company for any tax advice.

         6. TAXES. The Grantee agrees to satisfy all applicable non-U.S.,
federal, state and local income and employment tax withholding obligations and
herewith delivers to the Company the full amount of such obligations or has made
arrangements acceptable to the Company to satisfy such obligations. If the
Company is required to satisfy any non-U.S., federal, state or local income or
employment tax withholding obligations as a result of such an early disposition,
the Grantee agrees to satisfy the amount of such withholding in a manner that
the Board prescribes.

                                        1
<PAGE>

         7. SUCCESSORS AND ASSIGNS. The Company may assign any of its rights
under this Exercise Notice to single or multiple assignees, and this agreement
shall inure to the benefit of the successors and assigns of the Company. Subject
to the restrictions on transfer herein set forth, this Exercise Notice shall be
binding upon the Grantee and his or her heirs, executors, administrators,
successors and assigns.

         8. HEADINGS. The captions used in this Exercise Notice are inserted for
convenience and shall not be deemed a part of this agreement for construction or
interpretation.

         9. DISPUTE RESOLUTION. The provisions of Section 17 of the Option
Agreement shall be the exclusive means of resolving disputes arising out of or
relating to this Exercise Notice.

         10. GOVERNING LAW; SEVERABILITY. This Exercise Notice is to be
construed in accordance with and governed by the internal laws of the State of
Texas without giving effect to any choice of law rule that would cause the
application of the laws of any jurisdiction other than the internal laws of the
State of Texas to the rights and duties of the parties. Should any provision of
this Exercise Notice be determined by a court of law to be illegal or
unenforceable, such provision shall be enforced to the fullest extent allowed by
law and the other provisions shall nevertheless remain effective and shall
remain enforceable.

         11. NOTICES. Any notice required or permitted hereunder shall be given
in writing and shall be deemed effectively given upon personal delivery, upon
deposit for delivery by an internationally recognized express mail courier
service or upon deposit in the United States mail by certified mail (if the
parties are within the United States), with postage and fees prepaid, addressed
to the other party at its address as shown below beneath its signature, or to
such other address as such party may designate in writing from time to time to
the other party.

         12. FURTHER INSTRUMENTS. The parties agree to execute such further
instruments and to take such further action as may be reasonably necessary to
carry out the purposes and intent of this agreement.

         13. ENTIRE AGREEMENT. The Notice and the Option Agreement are
incorporated herein by reference and together with this Exercise Notice
constitute the entire agreement of the parties with respect to the subject
matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and the Grantee with respect to the subject matter
hereof, and may not be modified adversely to the Grantee's interest except by
means of a writing signed by the Company and the Grantee. Nothing in the Notice
the Option Agreement and this Exercise Notice (except as expressly provided
therein) is intended to confer any rights or remedies on any persons other than
the parties.

                                        2
<PAGE>

Submitted by:                            Accepted by:

GRANTEE:                                 CRDENTIA CORP.

                                         By:    --------------------------------

---------------------------------        Title: --------------------------------
           (Signature)

ADDRESS:                                 ADDRESS:

---------------------------------        14114 Dallas Parkway, Suite 600
                                         Dallas, Texas  75254
---------------------------------

                                        3
<PAGE>

                                   EXHIBIT B
                                   ---------

                      INVESTMENT REPRESENTATION STATEMENT
                      -----------------------------------

GRANTEE:                      William S. Leftwich

COMPANY:                      CRDENTIA CORP.

SECURITY:                     COMMON STOCK

AMOUNT:
                              ----------------------------------------------
DATE:
                              ----------------------------------------------

In connection with the purchase of the above-listed Securities, the undersigned
Grantee represents to the Company the following:

         (a) Grantee is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision to acquire the Securities. Grantee is
acquiring these Securities for investment for Grantee's own account only and not
with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act of 1933, as amended (the "Securities
Act").

         (b) Grantee acknowledges and understands that the Securities constitute
"restricted securities" under the Securities Act and have not been registered
under the Securities Act in reliance upon a specific exemption therefrom, which
exemption depends upon among other things, the bona fide nature of Grantee's
investment intent as expressed herein. Grantee further understands that the
Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available.
Grantee further acknowledges and understands that the Company is under no
obligation to register the Securities. Grantee understands that the certificate
evidencing the Securities will be imprinted with a legend which prohibits the
transfer of the Securities unless they are registered or such registration is
not required in the opinion of counsel satisfactory to the Company.

         (c) Grantee is familiar with the provisions of Rule 701 and Rule 144,
each promulgated under the Securities Act, which, in substance, permit limited
public resale of "restricted securities" acquired, directly or indirectly from
the issuer thereof, in a non-public offering subject to the satisfaction of
certain conditions. Rule 701 provides that if the issuer qualifies under Rule
701 at the time of the grant of the Option to the Grantee, the exercise will be
exempt from registration under the Securities Act. In the event the Company
becomes subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer
period as any market stand-off agreement may require) the Securities exempt
under Rule 701 may be resold, subject to the satisfaction of certain of the
conditions specified by Rule 144, including: (1) the resale being made through a
broker in an unsolicited "broker's transaction" or in transactions directly with
a market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2) the availability of certain public
information about the Company, (3) the amount of Securities being sold during

                                        1
<PAGE>

any three month period not exceeding the limitations specified in Rule 144(e),
and (4) the timely filing of a Form 144, if applicable.

         In the event that the Company does not qualify under Rule 701 at the
time of grant of the Option, then the Securities may be resold in certain
limited circumstances subject to the provisions of Rule 144, which requires the
resale to occur not less than one year after the later of the date the
Securities were sold by the Company or the date the Securities were sold by an
affiliate of the Company, within the meaning of Rule 144; and, in the case of
acquisition of the Securities by an affiliate, or by a non-affiliate who
subsequently holds the Securities less than two years, the satisfaction of the
conditions set forth in sections (1), (2), (3) and (4) of the paragraph
immediately above.

         (d) Grantee further understands that in the event all of the applicable
requirements of Rule 701 or 144 are not satisfied, registration under the
Securities Act, compliance with Regulation A, or some other registration
exemption will be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement
securities other than in a registered offering and otherwise than pursuant to
Rules 144 or 701 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such
persons and their respective brokers who participate in such transactions do so
at their own risk. Grantee understands that no assurances can be given that any
such other registration exemption will be available in such event.

         (e) Grantee represents that he or she is a resident of the state of
_________________.

                                       Signature of Grantee:

                                       ----------------------------------------

                                       Date:                          ,
                                             -------------------------  -------

                                        2<PAGE>

                                  EXHIBIT 10.8

   EXCLUSIVE MANUFACTURING, SALES, LICENSING AND SOFTWARE OWNERSHIP AGREEMENT

         This exclusive manufacturing, sales, and licensing and software
ownership agreement(hereafter Agreement)is entered into as of the 22nd day of
March, 2004 by and between MEDTRAK TECHNOLOGIES, INC., and Arizona Corporation
(hereafter MedTrak) and EYE DYNAMICS, Inc., a Nevada corporation (hereafter
EDI).

                                    RECITALS

         WHEREAS, EDI is engaged in the manufacture of various medical devices
and MedTrak is engaged in the marketing and sales of various medical devices;
and

         WHEREAS, the parties, having previously entered into an agreement on or
about March 19, 2001, documenting their business relationship, and tend that
this agreement shall affect the novation of superseded the prior agreement; and

         WHEREAS, MedTrak desires to have EDI be its sole and exclusive
manufacturer of infrared/video VNG systems (hereafter the VNG systems); and

         WHEREAS no quotas or established sales numbers will be applicable to
MedTrak, MedTrak agrees that an annual target of 300 systems is appropriate.
This shall be comprised of MedTrak 100 units, TRAK Series 150 units and IR/Video
50 units. MedTrak shall use its best efforts to achieve these target numbers.

         NOW, THEREFORE, in consideration of the matters set forth above and the
mutual covenants, promises, agreements, representations, and warranties of the
parties hereto, the parties to covenant, promise, agree, represent, and warrant
as follows:

         1. ACCURACY AND INCORPORATION OF RECITALS. The foregoing recitals are
true and correct and are incorporated herein as part of this agreement.

         2. EXCLUSIVE DEALINGS. EDI agrees to sell the VNG systems, and all
Electronystagmography systems and accessories developed by it, solely through
MedTrak and those entities specifically approved in writing by MedTrak. MedTrak
agrees to market and sell only those electronystagmography systems and
accessories thereto manufactured by EDI. This section is subject to the
provisions of paragraph six, below.

         3. ENG SYSTEMS. The ENG systems referred to in this agreement are the
two channel and four Channel infrared video ENG systems, which may be referred
to as videonystagmographs, complete with software and accessories, together with
software and hardware upgrades (which will hereafter be referred to individually
and collectively as the Products).

<PAGE>

         4. LICENSE OF CONFIDENTIAL AND PROPRIETARY INFORMATION.

         4.1      CONFIDENTIAL INFORMATION. EDI has developed, on its own accord
                  and is in possession of certain proprietary and confidential
                  source codes, schematics, and lists of contractors
                  (Confidential Information) related to the Product that is
                  utilized in the manufacture of the MedTrak and the EDI TRAK
                  Series and full clinical infrared/video VNG Systems. EDI
                  shall, within 15 days of execution of this Agreement deliver
                  the Confidential Information to Anker, Reed, Hymes &
                  Schreiber, a Law Corporation (hereafter Anker, Reed) for
                  storage and safekeeping.

         4.2      ACCESS TO EDI'S CONFIDENTIAL AND PROPRIETARY INFORMATION.
                  MedTrak acknowledges that it and its employees will be exposed
                  to and have access to proprietary information and trade
                  secrets (which together will hereafter be referred to as
                  Proprietary Information), provided to it by and belonging to
                  EDI, during the term of this Agreement.

                  4.2.1    MedTrak agrees to use such Confidential and
                           Proprietary Information only to the extent necessary
                           to perform its marketing and sales obligations under
                           this Agreement and will not disclose, during the term
                           of this Agreement, and at all times thereafter, any
                           of the Confidential and Proprietary Information to
                           any third party without the prior written consent of
                           EDI.

                  4.2.2    MedTrak acknowledges that irreparable injury will
                           result to EDI in the event of a breach of this
                           section four, and in the event of such breach, EDI
                           will be entitled to an injunction to restrain the
                           violation by MedTrak, its employees, and all persons
                           acting for or with it. Injunctive relief will be in
                           addition to any other remedies and damages available

         4.3      ACCESS TO MEDTRAK'S PROPRIETARY INFORMATION. EDI acknowledges
                  that it and its employees will be exposed to and have access
                  to confidential information and trade secrets (which together
                  will hereafter be referred to as Proprietary Information),
                  provided to it by and belonging to EDI, during the term of
                  this Agreement.

                  4.3.1    EDI agrees to use such Proprietary Information only
                           to the extent necessary to perform its development
                           and manufacturing obligations under this Agreement
                           and will not disclose during the term of this
                           agreement and at all times thereafter, any of the
                           Proprietary Information to any third party without
                           the prior written consent of MedTrak

                                       2

<PAGE>

                  4.3.2    EDI acknowledges that irreparable injury will result
                           to MedTrak in the event of a breach of this section
                           four, any event of such breach MedTrak will be
                           entitled to an injunction to restrain the violation
                           by EDI, its employees, and all persons acting for or
                           with it. Injunctive relief will be in addition to any
                           other remedies in damages available.

         5. OWNERSHIP AND LICENSES OF SOFTWARE. MedTrak shall be the exclusive
owner of the software, including upgrades, used in and by the MedTrak Brand and
EDI TRAK Series two channel ENG systems. All right, title, and interest,
including copyright rights, and said software is hereby vested, and future
upgrades will be vested, in MedTrak. MedTrak hereby grants EDI an exclusive
license to use the software during the effective term of this Agreement

         6. INABILITY OF EDI TO PROVIDE PRODUCTS. In the event EDI is not
capable of meeting MedTrak's sales requirements under paragraph two, above, if
EDI shall, within ten (10) days, inform MedTrak of such inability to perform.
Within ten (10) days after so informing MedTrak, EDI shall direct Anker, Reed to
make the Confidential Information available to MedTrak so as to ensure MedTrak's
ability to continue to manufacture the Products. If the inability to provide
products is temporary, EDI may grant permission to MedTrak to have the Products
manufactured by an alternative supplier, which supplier must first be approved
by EDI. In the event that MedTrak utilizes the Confidential Information made
available to them pursuant to paragraph 4.1, above, MedTrak will compensate EDI
for each Product not manufactured by EDI in an amount equal to 10% of MedTrak's
then current cost to purchase the Product from the EDI

         7. Warranties, Support and Repairs. EDI shall provide each end-user of
the Product with EDI's standard warranty and provide technical support and
repairs consistent with its warranty obligations.

         7.1 MEDTRAK WARRANTIES. MedTrak will not make any representation or
         give any warranties or guarantees to any person with respect to any of
         the Products or related services, other than those representations,
         warranties, or guarantees that EDI has specifically authorized.

         8. PURCHASE ORDERS. Each sale of any product hereunder shall be
initiated by MedTrak's delivery to EDI of a written purchase order specifying,
in reasonable detail, the type, quantity, delivery date, and shipping
destination information for the Product ordered (hereafter Purchase Order). No
Purchase Order will be binding an EDI until accepted, in writing by EDI. If any
Purchase Order is not rejected, in writing, delivered to MedTrak by EDI within
three (3)business days of EDI's receipt of the Purchase Order, said Purchase
Order will be deemed excepted as submitted.

         9.  DELIVERY.

                                       3

<PAGE>

         9.1      TYPE OF DELIVERY. All Products delivered will be FOB EDI's
                  plant or other place of shipment. EDI will use its best
                  efforts to deliver Products by the applicable delivery date to
                  the destination specified in each Purchase Order. All customs
                  duties, costs, taxes, insurance premiums, and other expensive
                  expenses relating to such transportation and delivery will be
                  at the recipients expense.

         9.2      PACKAGING. EDI will package the product in its standard
                  shipping packages.

         9.3      SET UP AND COMPLIANCE. MedTrak will be responsible for
                  assisting end-users with setting out and ensuring Product
                  compliance with Product specifications at the time of setup.

         10. PRICE, COMMISSION, AND PAYMENT.

         10.1     PRICE. EDI will establish a wholesale price for each Product,
                  which will be set forth on exhibit A. attached hereto. MedTrak
                  will pay EDI the wholesale price for each product sold by
                  MedTrak. Payment terms shall be NET 15 days after date of
                  invoice. EDI will only have the right to sell the Products to
                  the United States military and government, ENT physicians,
                  Otologists, and Audiologists. In addition, EDI will continue
                  to sell to overseas clients for export of products.

         10.2     COMMISSION. EDI will pay MedTrak a commission of four thousand
                  dollars ($4000) for each sale of an ENG system sold by EDI.

         10.3     PAYMENT. EDI to make all payments due hereunder to MedTrak on
                  the 15th day of each month for all sales paid for in the
                  previous month.

         10.4     LEADS. Leads shall be registered with MedTrak and shall be
                  controlled and distributed at the discretion of MedTrak.

         11.  TERMINATION.

         11.1     TERM. Unless earlier terminated pursuant to the terms thereof,
                  this Agreement will continue in effect for a period of 10
                  years (the Initial Term) and will be renewed for three
                  successive three year periods (Additional Terms), thereafter
                  unless notice of termination is given, in writing, by either
                  party at least 90 days prior to the end of the Initial Term or
                  any Additional Term, as the case may be.

         11.2     TERMINATION. This Agreement may be terminated upon mutual
                  written agreement of the parties.

         11.3     DEFAULT. If either party materially defaults in the
                  performance of any material agreement, condition, or covenant
                  of this Agreement, and such default or noncompliance will not
                  have been remedied, or steps initiated to remedy the same to
                  the other parties reasonable satisfaction within 30 days after
                  receipt of notice specifying the default, the party not in
                  default may terminate this agreement.

                                       4

<PAGE>

         12. INDEMNIFICATION. The parties agree that each party is solely
responsible for the performance of its duties, and each agrees to indemnify and
hold the other harmless from and against any and all claims asserted against the
other for loss or damage to property including claims for economic and business
injury, to persons or firms and all injury or death to third persons, including
all expenses incident to any of the foregoing claims, in any way arising out of
or relating to the conduct of such party's business and performance under this
Agreement. Each party further agrees to defend the other and the other's agents
and employees from and against any claim, demand, cause of action, damage, loss,
cost or expense arising from or in connection with its actions or failures to
act. Neither party may take any action that would have the effect of causing the
other to be in violation of any rules, decrees, laws, or regulations.

         13. INJUNCTIVE RELIEF. In the event the EDI breaches or threatens to
breach its obligations (a) to maintain the confidentiality of information
provided to it by MedTrak or (b)of MedTrak's copyright rights, MedTrak will be
entitled to an injunction to restrain the violation or threatened violation by
EDI, its principals, or its employees. Injunctive relief will be in addition to
any other remedies and damages available. All available remedies will be
cumulative.

         14. MISCELLANEOUS.

         14.1     ENTIRE AGREEMENT. This Agreement contains the entire agreement
                  of the parties regarding the subject matter hereof and
                  supersedes all prior agreements, understandings, and
                  negotiations regarding the same.

         14.2     ASSIGNMENT. This Agreement may not be assigned by either party
                  without the prior written consent of the other party.

         14.3     SEVERABILITY. If any provision of this Agreement will be held
                  illegal or unenforceable, that provision will be limited or
                  eliminated to the minimum extent necessary so this Agreement
                  will otherwise remain in full force and effect.

         14.4     FURTHER ASSURANCES. Each party hereto agrees to execute,
                  acknowledge, and deliver such further instruments, and to do
                  all such other acts as may be necessary or appropriate in
                  order to carry out the purposes and intent of this Agreement.

         14.5     USE OF PARTY'S NAME. No right, express or implied, is granted
                  by this agreement to either party to use in any manner not
                  expressly provided for herein the name of the other party or
                  any other trademark or trade name of the other in connection
                  with the performance of this agreement.

                                       5

<PAGE>

         14.6     NOTICE AND REPORTS. All notices, demands, requests, elections
                  or other communications required or permitted to be given by
                  any party to the other shall be in writing and shall be (a)
                  personally delivered; (b) sent via facsimile transmission; or
                  (c) deposited in the United States mail, first-class certified
                  postage prepaid, return receipt requested, and addressed to
                  the parties as follows:

                           To EDI:           2301 W. 205th Street, Number 102
                                             Torrance, CA 90501
                                             Facsimile: 310.328.0697

                           To MedTrak:       10182 E. Cactus Road
                                             Scottsdale, AZ 85260
                                             Facsimile: 413.826.7905

         Notices, demands, requests, elections, or other communications will, if
         personally delivered, be effective upon receipt; if mailed, the
         effective upon the earlier of (a) actual receipt, (b) four days after
         first being deposited in the United States mail as indicated by the
         postmark thereon; or (c)if sent via facsimile, the effective upon
         delivery so long as the sender's facsimile machine provides written
         proof of successful transmission. Notice of such change of address is
         in the manner provided for the giving of other notices.

         14.7     RELATIONSHIPS OF THE PARTIES. Nothing contained in this
                  agreement is intended to be construed so as to constitute an
                  EDI and MedTrak as partners or joint venturers with each
                  other. Either party hereto shall have any express or implied
                  right or authority to assume or create any obligations on
                  behalf of or in the name of the other party or to buy in the
                  other party to any contract, agreement, or undertaking with
                  any third party.

         14.8     WAIVER AND MODIFICATION. The waiver by either party of a
                  breach of any provision contained herein will in no way be
                  construed as a waiver of any subsequent breach of such
                  provision or the waiver of the provision itself. This
                  Agreement may not be changed, modified, amended, or
                  supplemented except by written instrument signed by both
                  parties.

         14.9     APPLICABLE LAW. This agreement shall be governed by and
                  construed in accordance with the laws of the State of Arizona,
                  without regard to conflict of laws provisions. Venue for any
                  action to enforce or interpret the provisions of this
                  agreement shall be Phoenix, Arizona. The prevailing party in
                  any legal action to enforce or interpret this agreement shall
                  be entitled to reasonable costs and attorney's fees.

         14.10    ATTORNEY'S FEES. If any action at law or in equity or by
                  alternative dispute resolution mechanism, including an action
                  for declaratory relief, is brought to enforce or interpret the
                  provisions of this agreement, prevailing party, or
                  substantially prevailing party, will be entitled to reasonable
                  costs, expenses, and attorney's fees in addition to any other
                  relief to which the party may be entitled. The attorney's fees
                  may be set by the tribunal in the same action or a separate
                  action brought for that purpose.

                                       6

<PAGE>

         14.11    CAPTIONS. Paragraph captions are for convenience only and no
                  way to be construed to define, limit, or affect the
                  construction or interpretation hereof.

         14.12    FORCE MAJEURE. A party shall not be liable for nonperformance
                  or delay in performance (other than of obligations regarding
                  payment of money or confidentiality) caused by any event
                  reasonably beyond the control of such party including, but not
                  limited to wars, hostilities, revolutions, riots, civil
                  commotion, national emergency, strikes, lockouts,
                  unavailability of supplies, epidemics, fire, flood,
                  earthquake, force of nature, explosion, embargo, or any other
                  act of God, or any law, proclamation, regulation, ordinance,
                  or other act or order of any court, government or governmental
                  agency.

         14.13    COUNTERPARTS. This Agreement may be executed in any number of
                  counterparts, each of which will be deemed to be an original
                  as against any party whose signature appears here on, and all
                  of which will together constitute one and the same instrument.
                  This Agreement will become binding in one or more counterparts
                  hereof, individually or taken together, they are the
                  signatures of all the parties reflected here on as the
                  signatories.

IN WITNESS WHEREOF, the parties have executed this agreement to be effective as
of the date first written above.

MEDTRAK TECHNOLOGIES, INC.                       EYE DYNAMICS, INC.
an Arizona corporation,                          a Nevada corporation,

/S/ MEL SHADOWENS                                /S/ CHARLES E. PHILLIPS
-----------------                                -----------------------
Mel Shadowens, Ph.D., Member                     Charles E. Phillips, President

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]